ArticleFEBS open bio2016
microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma.
Article in FEBS open bio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2024Pooled it
- Prognostic Value of MicroRNA-497 in Various Cancers: A Systematic Review and Meta-Analysis.Disease markers · 2019Pooled it
- Retraction Note: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.Cancer cell international · 2026Article
- The Expression of Circulating miR-497 and Metadherin in Hepatocellular Carcinoma: Relation to the Tumor Characteristics and Patients' Survival.Medicina (Kaunas, Lithuania) · 2021Article
- MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.Biomedicines · 2021Review
- Regulation of microRNA-497 expression in human cancer.Oncology letters · 2021Review
- MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients.International journal of genomics · 2021Article
- LINC02476 Promotes the Malignant Phenotype of Hepatocellular Carcinoma by Sponging miR-497 and Increasing HMGA2 Expression.OncoTargets and therapy · 2020Article
- Silencing of lncRNA MIR497HG via CRISPR/Cas13d Induces Bladder Cancer Progression Through Promoting the Crosstalk Between Hippo/Yap and TGF-β/Smad Signaling.Frontiers in molecular biosciences · 2020Article
- MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2.Oncology letters · 2019Article
- Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer.Cancer management and research · 2019Article
- MicroRNA-497-5p attenuates IL-1β-induced cartilage matrix degradation in chondrocytes via Wnt/β-catenin signal pathway.International journal of clinical and experimental pathology · 2019Article
- FGFR1 is an independent prognostic factor and can be regulated by miR-497 in gastric cancer progression.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.Journal of translational medicine · 2018Article
- Article
- Prognostic Role of MicroRNA-497 In Cancer Patients: A Meta-analysis.Journal of Cancer · 2018Article
- miR-497 inhibited proliferation, migration and invasion of thyroid papillary carcinoma cells by negatively regulating YAP1 expression.OncoTargets and therapy · 2018Article
- Article
- MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.Molecular medicine reports · 2017Article
- New Insights into the Epigenetics of Hepatocellular Carcinoma.BioMed research international · 2017Review
Corrections and comments
- Retraction · 2022-11-15Duplication of/in Image · Investigation by Third Party · Paper Mill · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/ED97AC4C77CF0EA59CB73E3FCFD949
- Retracted
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs (miRNAs) function as oncogenes or tumor suppressors in human cancers by targeting mRNAs for degradation and/or translational repression. miR-497 has been proposed as a tumor suppressive miRNA and its deregulation is observed in human cancers. However, the prognostic value of miR-497 and its underlying molecular pathways involved in the initiation and development of hepatocellular carcinoma (HCC) are poorly investigated. In the present study, we found that the mean level of miR-497 in HCC tissues was lower than that in adjacent nontumor tissues. Clinical data indicated that low expression of miR-497 was prominently associated with adverse prognostic features of HCC including high serum alpha-fetoprotein (AFP) level, large tumor size, high Edmondson-Steiner grading and advanced tumor-node-metastasis (TNM) stage. Furthermore, miR-497 was an independent prognostic factor for indicating both 5-year overall survival and disease-free survival of HCC patients. Gain- and loss-of-function studies showed that miR-497 reduced cell proliferation and induced apoptosis in HCC cells. Yes-associated protein 1 (YAP1) was identified as a direct target of miR-497 in HCC. An inverse correlation between YAP1 and miR-497 expression was observed in HCC tissues. Notably, YAP1 knockdown abrogated the effects of miR-497 deletion on HCC cells with decreased cell proliferation and increased apoptosis. In conclusion, we report that miR-497 is a potent prognostic indicator and may suppress tumor growth of HCC by targeting YAP1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.